(19) classified patients into three risk groups based on eight non-therapeutic risk factors: age, tumor location, pathologic T stage, number of positive nodes, LVI, histological grade, hormonal receptor, and HER2 status. This evidence concerns the gene ERBB2 and neoplasm.